dc.contributor.author | Karalis, T | |
dc.contributor.author | Poulogiannis, G | |
dc.coverage.spatial | Switzerland | |
dc.date.accessioned | 2024-07-03T12:44:46Z | |
dc.date.available | 2024-07-03T12:44:46Z | |
dc.date.issued | 2024-04-04 | |
dc.identifier | ARTN 629 | |
dc.identifier | cells13070629 | |
dc.identifier.citation | Cells, 2024, 13 (7), pp. 629 - | en_US |
dc.identifier.issn | 2073-4409 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6285 | |
dc.identifier.eissn | 2073-4409 | |
dc.identifier.eissn | 2073-4409 | |
dc.identifier.doi | 10.3390/cells13070629 | |
dc.identifier.doi | 10.3390/cells13070629 | |
dc.description.abstract | Lysophosphatidic acid (LPA) is a phospholipid that displays potent signalling activities that are regulated in both an autocrine and paracrine manner. It can be found both extra- and intracellularly, where it interacts with different receptors to activate signalling pathways that regulate a plethora of cellular processes, including mitosis, proliferation and migration. LPA metabolism is complex, and its biosynthesis and catabolism are under tight control to ensure proper LPA levels in the body. In cancer patient specimens, LPA levels are frequently higher compared to those of healthy individuals and often correlate with poor responses and more aggressive disease. Accordingly, LPA, through promoting cancer cell migration and invasion, enhances the metastasis and dissemination of tumour cells. In this review, we summarise the role of LPA in the regulation of critical aspects of tumour biology and further discuss the available pre-clinical and clinical evidence regarding the feasibility and efficacy of targeting LPA metabolism for effective anticancer therapy. | |
dc.format | Electronic | |
dc.format.extent | 629 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.relation.ispartof | Cells | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | cancer metabolism | |
dc.subject | lysophosphatidic acid | |
dc.subject | oncometabolite | |
dc.subject | phospholipid | |
dc.subject | Humans | |
dc.subject | Neoplasms | |
dc.subject | Signal Transduction | |
dc.subject | Cell Movement | |
dc.subject | Lysophospholipids | |
dc.title | The Emerging Role of LPA as an Oncometabolite. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2024-04-01 | |
dc.date.updated | 2024-07-03T12:44:16Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.3390/cells13070629 | en_US |
rioxxterms.licenseref.startdate | 2024-04-04 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/38607068 | |
pubs.issue | 7 | |
pubs.organisational-group | ICR | |
pubs.organisational-group | ICR/Primary Group | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Cancer Biology/Signalling & Cancer Metabolism | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.3390/cells13070629 | |
pubs.volume | 13 | |
icr.researchteam | Signalling Cancer Metab | en_US |
dc.contributor.icrauthor | Karalis, Theodoros | |
dc.contributor.icrauthor | Poulogiannis, Georgios | |
icr.provenance | Deposited by Mr Arek Surman on 2024-07-03. Deposit type is initial. No. of files: 1. Files: The Emerging Role of LPA as an Oncometabolite.pdf | |